Inc Abiomed Net Worth

What's Inc Abiomed's mailing address?

Inc's mailing address filed with the SEC is 22 CHERRY HILL DR, , DANVERS, MA, 01923.

Insiders trading at Abiomed

Over the last 21 years, insiders at Abiomed have traded over $148,507,587 worth of Abiomed stock and bought 232,354 units worth $4,276,073 . The most active insiders traders include Michael R Minogue, Eric A Md Rose e David M Weber. On average, Abiomed executives and independent directors trade stock every 16 days with the average trade being worth of $5,341,900. The most recent stock trade was executed by Martin P Sutter on 17 February 2022, trading 4,000 units of ABMD stock currently worth $1,258,840.

What does Abiomed do?

Abiomed Europe GmbH, Aachen / Germany, as affiliate of Abiomed Inc. headquartered in Danvers, Massachusetts, USA, is a leading medical technology company in the field of circulatory support. Its products aim to enable heart recovery by improving blood circulation and/or heart pump function.

Abiomed executives and stock owners

Abiomed executives and other stock owners filed with the SEC include:

• Michael Minogue,
  Chairman of the Board, President, Chief Executive Officer
• Todd Trapp,
  Chief Financial Officer, Vice President
• Andrew Greenfield,
  Vice President, Chief Commercial Officer
• David Weber,
  Chief Operating Officer, Senior Vice President
• Michael R. Minogue,
  Chairman, CEO & Pres
• Michael Howley,
  Vice President and General Manager, Global Sales
• Todd A. Trapp,
  CFO & VP
• Dr. David M. Weber,
  Sr. VP & COO
• Marc A. Began,
  VP, Gen. Counsel & Sec.
• Andrew J. Greenfield,
  VP & Chief Commercial Officer
• Dorothy Puhy,
  Lead Independent Director
• Paul Thomas,
  Independent Director
• Martin Sutter,
  Independent Director
• Jeannine Rivet,
  Independent Director
• Christopher Van Gorder,
  Independent Director
• Eric Rose,
  Independent Director
• Marc Began,
  Vice President, General Counsel, Secretary
• Karen Mahoney,
  Head of Global HR
• Michael G. Howley,
  VP & GM of Global Sales
• Sarah Karr,
  Communications Mang.
• Ingrid Goldberg Ward,
  Director of Investor Relations
• Dr. Thorsten Siess Ph.D.,
  VP & CTO
• Henri A Termeer,
  Director
• Gorder Chris Van,
  Director
• William J Bolt,
  SVP, DA and QA
• Michael John Tomsicek,
  Vice President, CFO
• W Gerald Austen,
  Director
• Myron L Rolle,
  Director
• Louis E Lataif,
  Director
• Robert Bowen,
  Chief Financial Officer
• Ronald W Dollens,
  Director
• Daniel J Sutherby,
  CFO
• Inc Abiomed,
  Director
• Connell Desmond Jr O,
  Director
• Paul Fireman,
  Director
• Javier Jimenez,
  VP Operations
• Anthony W Bailey,
  VP, Business Development
• David M Lederman,
  Chairman, CEO & President
• Charles B Haaser,
  Principal Financial Officer
• Eugene D Rabe,
  SVP, Global Sales & Services
• Christopher D Macdonald,
  SVP Global Sales
• Sheila Marie Flaherty,
  VP, General Counsel
• Robert T V Kung,
  SVP, Chief Scientific Officer
• Edward E Berger,
  VP, Strat. Plan & Ext. Comm.
• Patricia A. Fitch,
  Vice President of Sales
• Raymond J Kelley,
  VP Marketing
• David Gottlieb,
  Director
• John F Obrien,
  Director
• Gary Stickel,
  VP of HR
• Karim Benali,
  VP Product Development
• Robert Farra,
  VP Engineering & Manufacturing
• Stephen C Mc Evoy,
  VP and General Counsel
• Paula A Johnson,
  Director